Each week, we like to take a moment to boil down the biggest news from the most influential companies in the pharmaceuticals industry, and tell our viewers what that news means for you. We call that segment our Big Pharma Roundup.
In this week's installment, diabetes titan Novo Nordisk just received a credit rating upgrade from Moody's; already at Aa2, the company has been elevated to Aa1, which is only one grade away from Moody's ultimate Aaa rating. Motley Fool health care analyst Brenton Flynn highlights some of the new drugs that will contribute to NVO's solid growth.
While Novo Nordisk is the premier diabetes player, there's more than one way to play the trend. Still down around 90% from its highs less than a decade ago, there's been no giant leap for MannKind shareholders. The debate rages over whether the company's revolutionary inhalable insulin, slated to go in front of the FDA next year, will be a complete flop or a massive blockbuster success. In this brand new premium report on MannKind, we outline every key topic investors have to know with this risky stock. It also comes with a full year of analyst updates to keep you covered as key news develops, so don't miss out — simply click here now to claim your copy today.
The article This Top Big Pharma Stock Just Got an Upgrade originally appeared on Fool.com.Brenton Flynn, Max Macaluso, and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.